1 / 7

Flow of Participants Through the Trial

Flow of Participants Through the Trial. IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445. Baseline Participant Characteristics. IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445. Baseline and Follow-up Levels of Lipids and Lipoproteins*.

carrie
Télécharger la présentation

Flow of Participants Through the Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Flow of Participants Through the Trial IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  2. Baseline Participant Characteristics IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  3. Baseline and Follow-up Levels of Lipids and Lipoproteins* IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  4. Incidence of and Hazard Ratios for Primary and Secondary Efficacy Outcomes IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  5. Cumulative Hazard of Cardiovascular Disease IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  6. Cumulative Hazard of Nonfatal Myocardial Infarction, Stroke, Coronary Revascularization, and Peripheral Artery Disease IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

  7. Frequency of Adverse Events and Most Relevant Liver Enzyme Elevations IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445

More Related